CRIS Current Research Information System

TADOLINI, MARINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.801
EU - Europa 1.992
AS - Asia 857
AF - Africa 139
OC - Oceania 11
SA - Sud America 11
Continente sconosciuto - Info sul continente non disponibili 2
Totale 5.813
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.787
GB - Regno Unito 786
SE - Svezia 382
CN - Cina 305
SG - Singapore 228
DE - Germania 220
IT - Italia 174
VN - Vietnam 135
IN - India 110
RU - Federazione Russa 96
IE - Irlanda 86
FR - Francia 76
CI - Costa d'Avorio 51
ZA - Sudafrica 45
EE - Estonia 43
UA - Ucraina 36
TG - Togo 32
ID - Indonesia 22
CH - Svizzera 21
JO - Giordania 15
BG - Bulgaria 14
CA - Canada 13
BE - Belgio 12
FI - Finlandia 12
AU - Australia 11
GR - Grecia 10
NG - Nigeria 7
NL - Olanda 7
TW - Taiwan 7
BR - Brasile 6
JP - Giappone 6
PK - Pakistan 6
KR - Corea 4
AT - Austria 3
PH - Filippine 3
PL - Polonia 3
RO - Romania 3
UZ - Uzbekistan 3
BO - Bolivia 2
CL - Cile 2
ET - Etiopia 2
EU - Europa 2
HK - Hong Kong 2
IR - Iran 2
LB - Libano 2
LT - Lituania 2
TR - Turchia 2
AL - Albania 1
BD - Bangladesh 1
BY - Bielorussia 1
CY - Cipro 1
HU - Ungheria 1
IL - Israele 1
JM - Giamaica 1
LA - Repubblica Popolare Democratica del Laos 1
MA - Marocco 1
MD - Moldavia 1
MK - Macedonia 1
PE - Perù 1
SA - Arabia Saudita 1
SC - Seychelles 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 5.813
Salva come PNG Salva come JPEG
Città #
Southend 745
Fairfield 378
Ashburn 273
Chandler 208
Singapore 202
Wilmington 186
Houston 180
Woodbridge 177
Seattle 163
Cambridge 147
Princeton 128
Ann Arbor 117
Dong Ket 88
Dublin 86
Nanjing 56
Bologna 53
Abidjan 51
Westminster 46
New York 45
Santa Clara 41
Padova 40
Dearborn 35
Lomé 32
San Diego 32
Saint Petersburg 30
Berlin 27
Beijing 20
Bern 19
Jakarta 17
Boardman 16
Nanchang 16
Amman 15
Falls Church 15
Des Moines 14
Hebei 14
Sofia 14
Jinan 13
Shenyang 13
Bremen 12
Brussels 12
Redwood City 11
Washington 10
Zhengzhou 10
Changsha 9
Helsinki 9
Frankfurt am Main 8
Guangzhou 8
Jiaxing 8
London 8
Redmond 8
Tianjin 8
Toronto 8
Milan 7
Norwalk 7
San Francisco 7
Shanghai 7
Turin 7
Chengdu 6
Harbin 6
Jacksonville 6
Los Angeles 6
Paris 6
Abeokuta 5
Chicago 5
Kunming 5
Medford 5
Olalla 5
Pune 5
San Jose 5
Shijiazhuang 5
Sydney 5
Tokyo 5
Buffalo 4
Bühl 4
Foshan 4
Fuzhou 4
Hefei 4
Karachi 4
Melbourne 4
Taiyuan 4
Taizhou 4
Chiyayi County 3
Costa Mesa 3
Florence 3
Hangzhou 3
Kaohsiung City 3
Lappeenranta 3
Mumbai 3
Padang 3
Pisa 3
Plauen 3
San Fernando City 3
Torino 3
Wuhan 3
Amsterdam 2
Anyang 2
Baotou 2
Belém 2
Bergamo 2
Chuncheon 2
Totale 4.083
Salva come PNG Salva come JPEG
Nome #
Trend of microbiologically-confirmed tuberculosis in a low-incidence setting with high immigration rates 361
Development and validation of a prediction model for severe respiratory failure in hospitalized patients with SARS-CoV-2 infection: a multicentre cohort study (PREDI-CO study) 131
Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review 125
Comparison of effectiveness and safety of imipenem/clavulanate-versus meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB 125
Diagnosis of smear-negative tuberculosis is greatly improved by Xpert MTB/RIF 124
Spinal tuberculosis: Proposed spinal infection multidisciplinary management project (SIMP) flow chart revision 122
First evaluation of QuantiFERON-TB gold plus performance in contact screening 121
Tuberculosis elimination: Theory and practice in Europe 121
Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: Early experiences and challenges 120
Crossborder travel and multidrugresistant tuberculosis (MDRTB) in Europe 117
Combined use of delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis: A systematic review 115
Liver transplantation is associated with good clinical outcome in patients with active tuberculosis and acute liver failure due to anti-tubercular treatment 114
Combining bedaquiline and delamanid to treat multidrug-resistant tuberculosis 113
Challenging MDR-TB clinical problems – The case for a new Global TB Consilium supporting the compassionate use of new anti-TB drugs 113
Multidetector CT urography in urogenital tuberculosis: use of reformatted images for the assessment of the radiological findings. A pictorial essay 112
Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine 111
Clinical impact of reninangiotensin system inhibitors on in-hospital mortality of patients with hypertension hospitalized for coronavirus disease 2019 111
Socioeconomic status and biomedical risk factors in migrants and native tuberculosis patients in Italy 105
Effectiveness and Safety of Imipenem-Clavulanate Added to an Optimized Background Regimen (OBR) Versus OBR Control Regimens in the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis 101
Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: A systematic review 100
Do we need a new Fleming époque: The nightmare of drug-resistant tuberculosis 99
New and repurposed drugs for pediatric multidrug-resistant tuberculosis practice-based recommendations 99
The first population-based national tuberculosis prevalence survey in Ethiopia, 2010-2011 97
Compassionate and optimum use of new tuberculosis drugs 97
Recommendations for treating children with drug-resistant tuberculosis 97
COVID-19 in patients with HIV-1 infection: a single-centre experience in northern Italy 95
Paediatric tuberculosis in Europe: Lessons from Denmark and inclusive strategies to consider 94
Human herpesvirus-8-related Kaposi’s sarcoma after liver transplantation successfully treated with cidofovir and liposomal daunorubicin. 94
Membranoproliferative glomerulonephritis associated with human immunodeficiency virus, hepatitis B and hepatitis C virus coinfection: case report and literature review. 93
Overview of fever of unknown origin in adult and paediatric patients 93
ERS/WHO Tuberculosis Consilium: Reporting of the initial 10 cases 92
Effectiveness and safety of meropenem/ clavulanate-containing regimens in the treatment of MDR- and XDR-TB 91
First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline 91
WHO strategies for the programmatic management of drug-resistant tuberculosis 90
Recommendations for the diagnosis of pediatric tuberculosis 90
First independent evaluation of QuantiFERON-TB Plus performance 89
ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: Case study of compassionate delamanid use 89
Systematic Tuberculosis Screening in Asylum Seekers in Italy 89
Active tuberculosis, sequelae and COVID-19 co-infection: First cohort of 49 cases 88
Supporting clinical management of the difficult-to-treat TB cases: The ERS-WHO TB Consilium 87
Faster for less: The new "shorter" regimen for multidrug-resistant tuberculosis 87
Recommendations Concerning the First-Line Treatment of Children with Tuberculosis 81
Recommendations Concerning the Therapeutic Approach to Immunocompromised Children with Tuberculosis 77
A new free-cost e-service supporting clinicians to manage their difficult-to-treat tuberculosis cases: The European respiratory society-World Health Organization tuberculosis consilium 74
Predictors of time to sputum smear conversion in patients with pulmonary tuberculosis under treatment 70
A multidrug resistant tuberculosis case treated with continuous infusion of meropenem in outpatient care 67
Introduction of bedaquiline for the treatment of multi-drug resistant tuberculosis at country level: implementation plan 66
Quantiferon-TB performs better in children, including infants, than in adults with active tuberculosis: a multicentre study 65
null 64
A new free-cost e-service supporting clinicians to manage their difficult-to-treat TB cases: The ERS-WHO TB consilium 61
Prospective evaluation of improving fluoroquinolone exposure using centralised therapeutic drug monitoring (TDM) in patients with tuberculosis (PERFECT): A study protocol of a prospective multicentre cohort study 58
null 57
Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort 57
Evaluation of trace calls by Xpert MTB/RIF ultra for clinical management in low TB burden settings 48
On tuberculosis and COVID-19 co-infection 43
National tuberculosis prevalence surveys in Africa, 2008–2016: an overview of results and lessons learned 41
Surveillance of adverse events in the treatment of drug-resistant tuberculosis: First global report 41
National population-based tuberculosis prevalence survey in Ghana, 2013 39
Tuberculosis, COVID-19 and migrants: Preliminary analysis of deaths occurring in 69 patients from two cohorts 38
Worldwide Effects of Coronavirus Disease Pandemic on Tuberculosis Services, January–April 2020 36
IGRA test for TB in COVID-19: role of corticosteroids 34
Country-specific lockdown measures in response to the COVID-19 pandemic and its impact on tuberculosis control: a global study 33
TB mortality in low-incidence countries: can we reduce it further? 31
Reducing tuberculosis transmission: A consensus document from the World Health Organization Regional Office for Europe 30
Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study 28
Gauging the impact of the COVID-19 pandemic on tuberculosis services: A global study 28
High TB burden and low notification rates in the Philippines: The 2016 national TB prevalence survey 27
Clinical standards for the dosing and management of TB drugs 24
Clinical standards for drug-susceptible pulmonary TB 18
National TB prevalence surveys in the COVID-19 era 18
COVID-19 Hampered Diagnosis of TB Infection in France, Italy, Spain and the United Kingdom 16
Clinical standards for the management of adverse effects during treatment for TB 16
Healthcare seeking patterns for TB symptoms: Findings from the first national TB prevalence survey of South Africa, 2017–2019 15
Team approach to manage difficult-to-treat TB cases: Experiences in Europe and beyond 15
Policy and programmatic directions for the Lesotho tuberculosis programme: Findings of the national tuberculosis prevalence survey, 2019 14
Prevalence of bacteriologically confirmed pulmonary tuberculosis in South Africa, 2017-19: a multistage, cluster-based, cross-sectional survey 14
Efficacy, safety, and tolerability of a 24-month treatment regimen including delamanid in a child with extensively drug-resistant tuberculosis: A case report and review of the literature 14
Update of drug-resistant tuberculosis treatment guidelines: A turning point 12
World Tuberculosis Day 2023 theme “Yes! We Can End TB!” 12
How We Treat Drug-Susceptible Pulmonary Tuberculosis: A Practical Guide for Clinicians 11
Long-term outcomes of the global tuberculosis and COVID-19 co-infection cohort 11
Drugs for treating infections caused by non-tubercular mycobacteria: a narrative review from the study group on mycobacteria of the Italian Society of Infectious Diseases and Tropical Medicine 10
Ten common myths about drug-susceptible TB 4
Vaccination in post-tuberculosis lung disease management: A review of the evidence 4
TB consilia and quality of tuberculosis management 2
Totale 6.027
Salva come PNG Salva come JPEG
Categoria #
all - tutte 16.880
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.880
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.258 0 0 0 74 153 173 216 206 187 113 65 71
2020/2021849 146 59 24 32 44 38 23 51 115 58 42 217
2021/20221.145 69 72 79 116 109 54 28 79 30 101 210 198
2022/20231.111 84 134 66 137 104 100 42 63 234 19 77 51
2023/2024470 30 62 37 50 53 108 14 21 31 36 16 12
2024/2025530 36 272 122 100 0 0 0 0 0 0 0 0
Totale 6.027